TCRX TScan Therapeutics, Inc.
Healthcare$1.07+0.94%ClosedMarket Cap: $65.3M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
1.42
P/S
7.09
EV/EBITDA
0.03
DCF Value
$-3.83
FCF Yield
-193.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
92.4%
Operating Margin
-1408.7%
Net Margin
-1360.6%
ROE
-91.9%
ROA
-61.5%
ROIC
-67.9%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $982.0K | 29.4% | $-29.1M | $-28.7M | $— | — |
| Q4 null | $2.6M | 100.0% | $-23.9M | $-23.0M | $— | — |
| FY null | $10.3M | 72.2% | $-135.8M | $-129.8M | $— | — |
| Q3 null | $2.5M | 100.0% | $-37.1M | $-35.7M | $— | — |
| Q2 null | $3.1M | 100.0% | $-38.7M | $-37.0M | $— | — |
| Q1 null | $2.2M | 100.0% | $-36.3M | $-34.1M | $— | — |
| Q4 null | $665.0K | 100.0% | $-36.7M | $-35.8M | $— | — |
| FY null | $2.8M | 100.0% | $-134.8M | $-127.5M | $— | — |
| Q3 null | $1.0M | 100.0% | $-32.6M | $-29.9M | $— | — |
| Q2 null | $536.0K | 100.0% | $-34.1M | $-31.7M | $— | — |
| Q1 null | $566.0K | 100.0% | $-31.4M | $-30.1M | $— | — |
| Q4 2023 | $7.2M | 82.2% | $-21.4M | $-19.6M | $-0.21 | — |